Genomic Health

Genomic Health, Inc.
Public
Traded as NASDAQ: GHDX
Russell 2000 Component
ISIN US37244C1018
Industry Genomics
Founded August 2000 (2000-08) in Redwood City, California, United States
Founder Randy Scott
Headquarters Redwood City, California, United States
Key people
  • Kimberly J. Popovits
  • (Chairman, President, & CEO)
  • G. Bradley Cole
  • (CFO)
Products Oncotype D
Revenue Increase US$ 340.75 million (2017)
Increase US$ -6.45 million (2017)
Increase US$ -3.86 million (2017)
Total assets Increase US$ 231.62 million (2017)
Total equity Increase US$ 188.29 million (2017)
Number of employees
 863 (2017)
Website www.genomichealth.com
Footnotes / references
[1][2][3]

Genomic Health is a company focusing on genetic research specifically in cancer detection, based out of Redwood City, California.[2]

History

Genomic Health, Inc. was founded in 2000 by Randy Scott, who had previously founded and been CEO at Incyte.[4] He formed the company after a close friend was diagnosed with cancer and had the idea for treatment based on the specific genome of their tumor.[5]

By 2003 Genomic Health had developed Oncotype DX, a genomic assay that quantified the likelihood of breast cancer recurrence.[6] This development took the company over three years and US$30,000,000 to complete and then had to convince skeptics at the time of the validity of genetic testing.[6]

In July 2005 Genomic Health filed for an initial public offering to sell up to US$75,000,000 in common stock. Investors at the time already included Versant Ventures and Kleiner Perkins Caufield & Byers.[7] On September 29, 2005 it was listed on the NASDAQ with the symbol GHDX with the initial share price of US$12 for 5016722 shares.[8]

Genomic Health also started a subsidiary in 2010, Invitae, with the goal of aggregating multiple genetics tests.[9] The company expanded with international headquarters in Geneva Switzerland and UK headquarters in London in 2011.[10]

See also

References

  1. ↑ "US SEC: Form 10-K Genomic Health, Inc". U.S. Securities and Exchange Commission. Retrieved April 3, 2018.
  2. 1 2 "GENOMIC HEALTH, INC". OpenCorporates. 13 December 2016. Retrieved 10 January 2017.
  3. ↑ Chaykowsk, Kathleen (10 April 2012). "CEO's dedication is behind Genomic Health's cancer tests". Peninsula Press. Retrieved 10 January 2017.
  4. ↑ Susan McKinnon; Sydel Silverman (1 June 2005). Complexities: Beyond Nature and Nurture. University of Chicago Press. p. 239. ISBN 978-0-226-50024-9. Retrieved 10 January 2017.
  5. ↑ Cook, Kevin (7 October 2013). "Genomic Health Has Sickly Stock Chart". Forbes. Retrieved 10 January 2017.
  6. 1 2 Chess, Robert; Denend, Lyn; Zenios, Stefanos (2006). "Genomic Health: Launching a Paradigm Shift ... and an Innovative New Test". Stanford Graduate School of Business. Retrieved 10 January 2017.
  7. ↑ Simmers, Tim (19 July 2005). "Genomic Health files for an IPO". East Bay Times. Retrieved 10 January 2017.
  8. ↑ "GENOMIC HEALTH INC (GHDX) IPO". NASDAQ. Retrieved 10 January 2017.
  9. ↑ Lash, Alex (20 October 2015). "What's Your DNA Worth? The Scramble To Cash In On the Genome". exome. Retrieved 10 January 2017.
  10. ↑ "Company Timeline & Milestones". Genomic Health. Retrieved 10 January 2017.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.